BRPI0515646B8 - proteína de fusão e formulação farmacêutica - Google Patents

proteína de fusão e formulação farmacêutica

Info

Publication number
BRPI0515646B8
BRPI0515646B8 BRPI0515646A BRPI0515646A BRPI0515646B8 BR PI0515646 B8 BRPI0515646 B8 BR PI0515646B8 BR PI0515646 A BRPI0515646 A BR PI0515646A BR PI0515646 A BRPI0515646 A BR PI0515646A BR PI0515646 B8 BRPI0515646 B8 BR PI0515646B8
Authority
BR
Brazil
Prior art keywords
infection
treatment
prevention
compositions
target cell
Prior art date
Application number
BRPI0515646A
Other languages
English (en)
Portuguese (pt)
Inventor
Fang Fang
Malakhov Michael
Original Assignee
Ansun Biopharma Inc
Fang Fang
Malakhov Michael
Nexbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc, Fang Fang, Malakhov Michael, Nexbio Inc filed Critical Ansun Biopharma Inc
Publication of BRPI0515646A publication Critical patent/BRPI0515646A/pt
Publication of BRPI0515646A8 publication Critical patent/BRPI0515646A8/pt
Publication of BRPI0515646B1 publication Critical patent/BRPI0515646B1/pt
Publication of BRPI0515646B8 publication Critical patent/BRPI0515646B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
BRPI0515646A 2004-09-10 2005-07-21 proteína de fusão e formulação farmacêutica BRPI0515646B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/939,262 US7807174B2 (en) 2002-11-22 2004-09-10 Class of therapeutic protein based molecules
US10/939,262 2004-09-10
PCT/US2005/025831 WO2006031291A2 (en) 2004-09-10 2005-07-21 A novel class of therapeutic protein based molecules

Publications (4)

Publication Number Publication Date
BRPI0515646A BRPI0515646A (pt) 2008-07-15
BRPI0515646A8 BRPI0515646A8 (pt) 2017-04-04
BRPI0515646B1 BRPI0515646B1 (pt) 2020-10-13
BRPI0515646B8 true BRPI0515646B8 (pt) 2021-05-25

Family

ID=36060467

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515646A BRPI0515646B8 (pt) 2004-09-10 2005-07-21 proteína de fusão e formulação farmacêutica

Country Status (16)

Country Link
US (2) US7807174B2 (enExample)
EP (4) EP1786902B1 (enExample)
JP (2) JP4764881B2 (enExample)
KR (1) KR20070064619A (enExample)
CN (2) CN104017787B (enExample)
AU (1) AU2005285461B2 (enExample)
BR (1) BRPI0515646B8 (enExample)
CA (2) CA2578050C (enExample)
DK (3) DK3018204T3 (enExample)
ES (3) ES2626845T3 (enExample)
IL (3) IL181779A (enExample)
PT (3) PT3241898T (enExample)
RU (1) RU2468080C2 (enExample)
TR (1) TR201905393T4 (enExample)
WO (1) WO2006031291A2 (enExample)
ZA (1) ZA200702915B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US8512710B2 (en) * 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US8084036B2 (en) * 2002-11-22 2011-12-27 Nexbio, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
CN101002512B (zh) * 2004-11-10 2013-12-04 日立化成株式会社 附有粘着辅助剂的金属箔及使用其的印刷配线板
CA2627323A1 (en) * 2005-10-25 2007-05-03 Mnd Diagnostic Ltd. Compositions for- detecting of influenza viruses and kits and methods using same
AU2015215955B2 (en) * 2006-01-24 2016-12-01 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
US20070190163A1 (en) 2006-01-24 2007-08-16 Malaknov Michael P Technology for preparation of macromolecular microspheres
AU2013237761B8 (en) * 2006-01-24 2015-06-04 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
US8273381B1 (en) * 2006-04-14 2012-09-25 Auburn University Compositions for and methods of controlling olfactory responses to odorants
US20100143972A1 (en) * 2006-12-14 2010-06-10 Horswill Alexander R Method of Making Cyclic Polypeptides with Inteins
EP2113027B1 (en) * 2007-02-20 2014-06-18 DSM IP Assets B.V. Novel sialidase
BRPI0815057B8 (pt) 2007-08-03 2021-05-25 Romark Laboratories Lc composto, composição farmacêutica, e, uso de um composto
EA021587B1 (ru) 2009-05-12 2015-07-30 РОМАРК ЛЭБОРЕТЕРИЗ Эл. Си. Соединения галогеналкилгетероарилбензамида
EA030679B1 (ru) * 2009-06-26 2018-09-28 РОМАРК ЛЭБОРЕТЕРИЗ Эл.Си. Соединения и способы лечения гриппа
EP2459714A1 (en) * 2009-07-31 2012-06-06 Danisco US Inc. Proteases with modified pre-pro regions
CN102711807A (zh) * 2009-11-06 2012-10-03 耐百生物制药有限公司 用于在呼吸道中进行治疗和预防的方法、化合物和组合物
JP2015508780A (ja) 2012-02-17 2015-03-23 アンサン バイオファーマ，インコーポレイテッド 免疫不全患者のインフルエンザ及びパラインフルエンザウイルスを処置するための方法、化合物、及び組成物
EP2877204A2 (en) * 2012-06-28 2015-06-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
CA2896057C (en) 2012-12-24 2023-03-14 Maxine Bauzon Short-acting factor vii polypeptides
CN110295114A (zh) * 2013-03-15 2019-10-01 安迅生物制药公司 蛋白纯化的新颖方法
WO2014197485A1 (en) * 2013-06-03 2014-12-11 Ansun Biopharma, Inc. Anti-viral therapeutic for infection of the eye
WO2014201034A2 (en) * 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment for polyomavirus infection
US20160120961A1 (en) * 2013-06-10 2016-05-05 Ansun Biopharma, Inc. Treatment of merkel cell polyomavirus infection
WO2015184356A1 (en) 2014-05-30 2015-12-03 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016115616A1 (en) * 2015-01-21 2016-07-28 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of cellular proteases as treatment for influenza
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG10202100652VA (en) * 2015-07-21 2021-03-30 Univ Jefferson Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
EP3458085B1 (en) 2016-05-20 2022-12-07 Octapharma AG Glycosylated vwf fusion proteins with improved pharmacokinetics
US11459398B2 (en) 2016-07-01 2022-10-04 The Board Of Trustees Of The Leland Stanford Junior University Conjugates for targeted cell surface editing
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
ES2986557T3 (es) * 2017-05-26 2024-11-11 Genovis Ab Enzimas para el análisis de glucanos
JP2020533404A (ja) 2017-09-05 2020-11-19 グラディエーター バイオサイエンシーズ インコーポレイテッド 細胞内送達法
MX2020007024A (es) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
GB201800274D0 (en) * 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201803197D0 (en) 2018-02-27 2018-04-11 Pneumagen Ltd Viral treatment
CN112739374A (zh) * 2018-07-20 2021-04-30 安迅生物制药公司 唾液酸酶向癌细胞、免疫细胞和肿瘤微环境的递送
CN109991649B (zh) * 2019-03-26 2021-04-06 华中科技大学 一种制备无机闪烁体膜的方法
JP7343890B2 (ja) * 2019-04-26 2023-09-13 国立大学法人東海国立大学機構 シアリダーゼ活性を有する酵素剤及びその利用
CN110038122A (zh) * 2019-05-23 2019-07-23 武汉真福医药股份有限公司 枯草杆菌纤溶酶在治疗支气管炎药物中的应用
US12245754B2 (en) 2019-07-03 2025-03-11 Aillis Inc. Pharmaceutical composition for treating influenza virus infections
CN111450236B (zh) * 2020-02-25 2023-04-07 西北大学 一种用于阻断冠状病毒感染的制剂
WO2021217053A1 (en) * 2020-04-24 2021-10-28 Rezolute, Inc. Plasma kallikrein inhibitors for the treatment of ards and related conditions
US20230218794A1 (en) * 2020-06-10 2023-07-13 The Penn State Research Foundation Process and system to lessen human coronavirus transmission and spread
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
WO2022261290A1 (en) * 2021-06-09 2022-12-15 Microbial Machines, Inc. Engineered microorganisms for detection of diseased cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
DE286239T1 (de) * 1987-03-10 1994-02-24 New England Biolabs Inc Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist.
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
US5376633A (en) 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5985859A (en) * 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
DE69527924T2 (de) * 1994-06-14 2003-01-09 Genencor International, Inc. Hitzebeständige xylanasen
SI9620042A (sl) * 1995-02-27 1998-12-31 Gilead Sciences, Inc. Novi selektivni inhibitorji virusnih ali bakterijskih neuraminidaz
GB9513683D0 (en) * 1995-07-05 1995-09-06 Ciba Geigy Ag Products
AU5546898A (en) 1997-01-14 1998-08-07 Hopital Sainte-Justine Human lysosomal sialidase and therapeutic uses thereof
US6251392B1 (en) 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20020025320A1 (en) 1999-08-20 2002-02-28 Prosper Boyaka Sialidases as mucosal adjuvants
CN1405562A (zh) * 2002-10-24 2003-03-26 肖洪武 一种唾液酸酶测定试剂
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US8084036B2 (en) 2002-11-22 2011-12-27 Nexbio, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
DE10258400A1 (de) * 2002-12-13 2004-06-24 N.V. Nutricia Trans-Sialidasen aus Trypanosoma congolense
US20070190163A1 (en) 2006-01-24 2007-08-16 Malaknov Michael P Technology for preparation of macromolecular microspheres

Also Published As

Publication number Publication date
TR201905393T4 (tr) 2019-05-21
ES2721172T3 (es) 2019-07-29
PT3018204T (pt) 2017-07-13
ES2626845T3 (es) 2017-07-26
JP4764881B2 (ja) 2011-09-07
CN101426906A (zh) 2009-05-06
US20050112751A1 (en) 2005-05-26
US7807174B2 (en) 2010-10-05
RU2468080C2 (ru) 2012-11-27
IL207957A (en) 2016-10-31
EP3530734A1 (en) 2019-08-28
BRPI0515646A (pt) 2008-07-15
IL181779A (en) 2015-10-29
EP1786902B1 (en) 2015-09-09
EP1786902A2 (en) 2007-05-23
CA2578050A1 (en) 2006-03-23
PT3241898T (pt) 2019-05-20
AU2005285461B2 (en) 2011-03-03
DK1786902T3 (en) 2015-10-19
IL181779A0 (en) 2007-07-04
WO2006031291A3 (en) 2009-04-16
JP5307082B2 (ja) 2013-10-02
DK3241898T3 (en) 2019-04-29
CA2823429A1 (en) 2006-03-23
RU2007112502A (ru) 2008-10-20
US20090142327A1 (en) 2009-06-04
ES2554787T3 (es) 2015-12-23
KR20070064619A (ko) 2007-06-21
IL241227A0 (en) 2015-11-30
AU2005285461A1 (en) 2006-03-23
CN104017787A (zh) 2014-09-03
EP1786902A4 (en) 2009-12-09
JP2010279366A (ja) 2010-12-16
HK1224329A1 (en) 2017-08-18
BRPI0515646B1 (pt) 2020-10-13
EP3018204B1 (en) 2017-04-12
BRPI0515646A8 (pt) 2017-04-04
EP3241898A1 (en) 2017-11-08
EP3018204A1 (en) 2016-05-11
IL241227B (en) 2020-05-31
DK3018204T3 (en) 2017-07-31
EP3241898B1 (en) 2019-01-23
PT1786902E (pt) 2015-12-22
CA2578050C (en) 2015-04-21
CN104017787B (zh) 2017-03-29
ZA200702915B (en) 2008-11-26
WO2006031291A2 (en) 2006-03-23
HK1201562A1 (en) 2015-09-04
CA2823429C (en) 2019-06-04
IL207957A0 (en) 2010-12-30
CN101426906B (zh) 2013-06-26
US7645448B2 (en) 2010-01-12
JP2008512117A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
BRPI0515646B8 (pt) proteína de fusão e formulação farmacêutica
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BRPI0517463A (pt) inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BRPI1012749A8 (pt) molécula de ligação, variante funcional da molécula de ligação, imunoconjugado, composição farmacêutica, uso da molécula de ligação, molécula de ácido nucléico. vetor, hospedeiro, e , método para produzir uma molécula de ligação.
BR112022022456A2 (pt) Proteínas de ligação de repetição de anquirina e seus usos
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
NO20071048L (no) Amidoforbindelser og deres anvendelse som farmasoytika
BR112014007721A2 (pt) processos para preparar compostos úteis como inibidores de atr quinase
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BRPI0710671B8 (pt) uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BR112014006297A2 (pt) inibidores de n-[1-ciano-2-(fenil) etil]-2-azabiciclo [2.2.1] heptano-3-carboxamida de catepsina c, seus usos, e composição farmacêutica
BR112015005972A2 (pt) derivados do tipo amida de ácido benzoimidazol-carboxílico como moduladores do receptor apj
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
NO20064584L (no) Tetrahydropyridoindolderivater
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/36 , C12N 1/21 , C07H 21/04 , C12N 15/75

Ipc: C12N 9/36 (2006.01), C12N 1/21 (2006.01), C07H 21/

B25A Requested transfer of rights approved

Owner name: NEXBIO, INC. (US)

B25D Requested change of name of applicant approved

Owner name: ANSUN BIOPHARMA, INC. (US)

B25G Requested change of headquarter approved

Owner name: ANSUN BIOPHARMA, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF